

IPW

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
HUAH104

In Re Application Of: HEANG

MAR 07 2005

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/615,695	07/08/2003		21,658	1614	9695

Title: SYNTHESIS AND PHARMACEUTICALS OF NOVEL BIS-SUBSTITUTED ANTHRAQUINONE DERIVATIVES

Address to:

Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

37 CFR 1.97(b)

- The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

- The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

 the statement specified in 37 CFR 1.97(e);

OR

 the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.

HUAH104

In Re Application: HUANG

MAR 07 2005

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/615,695	07/08/2003		21,658	1614	9695

Title: SYNTHESIS AND PHARMACEUTICALS OF NOVEL BIS-SUBSTITUTED ANTHRAQUINONE DERIVATIVES

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

A check in the amount of _____ is attached.

The Director is hereby authorized to charge and credit Deposit Account No. as described below.

- Charge the amount of _____
- Credit any overpayment.
- Charge any additional fee required.

Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

MARCH 4, 2005

(Date)

Signature of Person Mailing Correspondence

SUEZANN H. YORITA

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Signature

STEPHEN M. NIPPER

DYKAS, SHAVER & NIPPER, LLP

PO BOX 877

BOISE, ID 83701-0877

(208) 345-1122

REG. NO. 46,260

CC:

Dated: MARCH 4, 2005

INFORMATION DISCLOSURE CITATION <small>(Use several sheets if necessary)</small>			ATTY DOCKET NO. HUAH104		APPLICATION NO. 10/615,695			
			APPLICANT(S) HUANG		FILING DATE 07/08/2003			GROUP ART UNIT 1614
U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
U.S. PATENT APPLICATION PUBLICATIONS								
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS								
	DOCUMENT NUMBER	DATE	COUNTRY		CLASS	SUBCLASS	TRANSLATION	
							YES	NO
OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>								
		"SYNTHESIS AND CYTOTOXICITY OF 9-ALKOXY-1, 5-DICHLOROANTHRAcene DERIVATIVES IN MURINE AND HUMAN CULTURED TUMOR CELLS," 6 PAGES, ARTICLE NO. 0365-6233/01/0033						
		"SYNTHESIS OF SYMMETRICAL 1, 5-BISACYLOXYANTHRAQUINONE DERIVATIVES AND THEIR DUAL ACTIVITY OF CYTOTOXICITY AND LIPID PEROXIDATION," 6 PAGES, ARTICLE NO. 0365-6233/10/0481						
EXAMINER			DATE CONSIDERED					
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>								

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

ATTY DOCKET NO.
HUAH104

APPLICATION NO.
10/615,695

APPLICANT(S)
HUANG

FILING DATE
07/08/2003

GROUP ART UNIT
1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

U.S. PATENT APPLICATION PUBLICATIONS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		"CHROMOPHORE-MODIFIED ANTITUMOR ANTHRACENES. 1. CYTOTOXIC ACTIVITY OF 9-ACYLOXY 1,5-DICHLOROANTHRACENE ANALOGUES," THE CHINESE PHARMACEUTICAL JOURNAL, 2001, 53, PAGES 71-83
		"STUDIES ON ANTHRACENES. 1. HUMAN TELOMERASE INHIBITION AND LIPID PEROXIDATION OF 9-ACYLOXY 1,5-DICHLOROANTHRACENE DERIVATIVES," CHEM. PHARM. BULL. 49(8) PAGES 969-973 (2001)

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

ATTY DOCKET NO.
HUAH104

APPLICATION NO.
10/615,695

APPLICANT(S)
HUANG

FILING DATE
07/08/2003

GROUP ART UNIT
1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

U.S. PATENT APPLICATION PUBLICATIONS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		"STUDIES ON ANTHRACENES. 2. SYNTHESIS AND CYTOTOXIC EVALUATION OF 9-ACYLOXY 1,8-DICHLOROANTHRACENE DERIVATIVES," CHEM. PHARM. BULL. 49(10) PAGES 1346-1349 (2001)
		"STUDIES ON ANTHRACENES. 3. SYNTHESIS, LIPID PEROXIDATION AND CYTOTOXIC EVALUATION OF 10-SUBSTITUTED 1,5-DICHLORO-9(10h)-ANTHRACENONE DERIVATIVES," CHEM. PHARM. BULL. 49(10), PAGES 1288-1291 (2001)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

ATTY DOCKET NO.
HUAH104

APPLICATION NO.
10/615,695

APPLICANT(S)
HUANG

FILING DATE
07/08/2003

GROUP ART UNIT
1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

U.S. PATENT APPLICATION PUBLICATIONS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

"ANTIPSORIATIC ANTHRONES WITH MODULATED REDOX PROPERTIES. 3, 10-THIO-SUBSTITUTED 1,8-DIHYDROXY-9(10H)-ANTHRACENONES AS INHIBITORS OF KERATINOCYTE GROWTH, 5-LIPOXYGENASE, AND THE FORMATION OF 12(S)-HETE IN MOUSE EPIDERMIS1," J. MED. CHEM. 1996, 39, PAGES 3132-3138

"SIMPLE ANALOGUES OF ANTHRALIN: UNUSUAL SPECIFICITY OF STRUCTURE AND ANTIPROLIFERATIVE ACTIVITY+," J. MED. CHEM. 1997, 40, PAGES 3773-3780

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

ATTY DOCKET NO.
HUAH104

APPLICATION NO.
10/615,695

APPLICANT(S)
HUANG

FILING DATE
07/08/2003

GROUP ART UNIT
1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

U.S. PATENT APPLICATION PUBLICATIONS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

"EVALUATION OF THE ANTI-INFLAMMATORY AND CYTOTOXIC EFFECTS OF ANTHRAQUINONES AND ANTHRACENES DERIVATIVES IN HUMAN LEUCOCYTES," JOURNAL OF PHARMACY AND PHARMACOLOGY, PAGES 915-919, 2004

"CHARACTERIZATION OF NOVEL 10-SUBSTITUTED 1,8-DIHYDROXY-9(10H)-ANTHRACENONE DERIVATIVES BY MASS SPECTROMETRY," PROC. NATL. SCI. COUNC. ROC(B), VOL. 24, NO. 1, 2000, PAGES 20-25

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

***EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.